Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.

Kamphuis AEM, Salvadori N, Mujuru HA, Bwakura-Dangarembizi M, Kisitu GP, Matovu F, Kaudha E, Mulindwa A, Jacobs TG, Than-In-At K, Cressey TR, Nardone A, Lallemant M, Colbers A, Burger DM, UNIVERSAL1 trial team

Open source

DOI: 10.1016/s2352-3018(26)00168-2
Published: 2026 Sep 7
Container: The lancet. HIV
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3018-26-00168-2,
  title = {Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.},
  author = {Kamphuis AEM and Salvadori N and Mujuru HA and Bwakura-Dangarembizi M and Kisitu GP and Matovu F and Kaudha E and Mulindwa A and Jacobs TG and Than-In-At K and Cressey TR and Nardone A and Lallemant M and Colbers A and Burger DM and UNIVERSAL1 trial team},
  year = {2026},
  journal = {The lancet. HIV},
  doi = {10.1016/s2352-3018(26)00168-2},
  url = {https://doi.org/10.1016/s2352-3018(26)00168-2}
}

RIS

TY  - JOUR
TI  - Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.
AU  - Kamphuis AEM
AU  - Salvadori N
AU  - Mujuru HA
AU  - Bwakura-Dangarembizi M
AU  - Kisitu GP
AU  - Matovu F
AU  - Kaudha E
AU  - Mulindwa A
AU  - Jacobs TG
AU  - Than-In-At K
AU  - Cressey TR
AU  - Nardone A
AU  - Lallemant M
AU  - Colbers A
AU  - Burger DM
AU  - UNIVERSAL1 trial team
PY  - 2026
JO  - The lancet. HIV
DO  - 10.1016/s2352-3018(26)00168-2
UR  - https://doi.org/10.1016/s2352-3018(26)00168-2
ER  -

APA

AEM, K., N, S., HA, M., M, B., GP, K., F, M., E, K., A, M., TG, J., K, T., TR, C., A, N., M, L., A, C., DM, B., & team, U. T. (2026). Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.. The lancet. HIV. https://doi.org/10.1016/s2352-3018(26)00168-2

Source records

pubmed · retrieved 2026-09-26T03:05:12.526Z